摘要
茚地普隆(Indiplon)是由美国Neurocrine公司和辉瑞(Pfizer)公司共同研发的一种新型非苯二氮卓类镇静催眠药物,作用于GABAA受体上的一个特定靶点,增强GABA的抑制活性,从而促进失眠患者的睡眠。该药物于2005年7月经美国FDA批准上市。与当前临床主流的作用于GABAA的催眠药相比,该药具有吸收迅速,起效快,药效持久,半衰期短,耐受性良好等优点,其临床市场价值非常明显。本文对茚地普隆的研究进展和合成路线进行了综述。
Indiplon is a new non-benzodiazepine sedative hypnotic drugs.developed by Neurocrine company and Pfizer company,acting on GABAA receptors on a specific target.enhancing the inhibitory activity of GABA,thus contributing to insomnia patients sleep.It has authorized by FDA in 2005.Compared with other sedative-hypnotic drugs that act on GABAA. Indiplon is sustained efficacy,short half-life.the advantages of well-tolerated.the clinical market value is obvions.
关键词
失眠
茚地普隆
综述
insomnia
indiplon
intermediate
synthesis
